Balancing the Risks of Restenosis and Stent Thrombosis in Bare-Metal Versus Drug-Eluting Stents
Authors:
- David J. CohenDCDavid J. Cohen
- Thomas GazianoTGThomas Gaziano
- Laura MauriLMLaura Mauri
Abstract
No abstract availableKeywords
This publication has 39 references indexed in Scilit:
- Twenty-Five–Year Trends in In-Hospital and Long-Term Outcome After Percutaneous Coronary InterventionCirculation, 2007
- Stent Thrombosis in Randomized Clinical Trials of Drug-Eluting StentsNew England Journal of Medicine, 2007
- Late Clinical Events After Clopidogrel Discontinuation May Limit the Benefit of Drug-Eluting StentsJACC, 2006
- Bare metal stent restenosis is not a benign clinical entityAmerican Heart Journal, 2006
- Correlates and Long-Term Outcomes of Angiographically Proven Stent Thrombosis With Sirolimus- and Paclitaxel-Eluting StentsCirculation, 2006
- Incidence, Predictors, and Outcome of Thrombosis After Successful Implantation of Drug-Eluting StentsJAMA, 2005
- Thirty-day incidence and six-month clinical outcome of thrombotic stent occlusion after bare-metal, sirolimus, or paclitaxel stent implantationJACC, 2005
- A Polymer-Based, Paclitaxel-Eluting Stent in Patients with Coronary Artery DiseaseNew England Journal of Medicine, 2004
- Sirolimus-Eluting Stents versus Standard Stents in Patients with Stenosis in a Native Coronary ArteryNew England Journal of Medicine, 2003
- Stent Thrombosis in the Modern EraCirculation, 2001